Literature DB >> 12051632

Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms.

Luoquan Wang1, Ana Ignat, Constantine A Axiotis.   

Abstract

Genetic alteration and loss of expression of tumor suppressor gene PTEN has been found in carcinomas of the breast, prostate, and endometrium, as well as in gliomas. PTEN expression in neural crest/neuroendocrine (NC/NE) tissues and in neoplasms has not been reported. This study examines PTEN expression in embryonal, fetal, and adult tissues by immunohistochemistry. The authors found high PTEN expression in embryonal, fetal, and adult NC/NE tissues. The authors also study the PTEN expression in NC/NE neoplasms (N = 37), including 5 melanocytic nevi, 2 melanomas, 9 carcinoids, 2 moderately differentiated neuroendocrine carcinomas, 13 poorly differentiated neuroendocrine carcinomas, 2 paragangliomas, 2 pheochromocytomas, 2 medullary thyroid carcinomas, and 1 neuroblastoma. All carcinoid tumors and melanocytic nevi showed moderate or strong immunostaining for PTEN. In contrast, the majority of poorly differentiated neuroendocrine carcinomas (7 of 13) were negative for PTEN (54%); the remainder showed diminished reactivity. The two melanomas studied were also negative for PTEN immunostaining. The paragangliomas, pheochromocytomas, medullary thyroid carcinomas, and neuroblastoma all showed a strong PTEN stain. The authors postulate that PTEN is a differentiation marker for NC/NE tissue and tumors and that loss of PTEN expression may represent an important step in the progression of NE tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051632     DOI: 10.1097/00129039-200206000-00008

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  25 in total

Review 1.  The potential role of mTOR inhibitors in the treatment of endocrine tumors.

Authors:  S Grozinsky-Glasberg; I Shimon
Journal:  J Endocrinol Invest       Date:  2010-05-05       Impact factor: 4.256

Review 2.  Signaling mechanisms in neuroendocrine tumors as targets for therapy.

Authors:  Barbara Zarebczan; Herbert Chen
Journal:  Endocrinol Metab Clin North Am       Date:  2010-12       Impact factor: 4.741

3.  VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Authors:  Scott R Silva; Kanika A Bowen; Piotr G Rychahou; Lindsey N Jackson; Heidi L Weiss; Eun Y Lee; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

Review 4.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 5.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

Review 6.  Targeted therapy in advanced well-differentiated neuroendocrine tumors.

Authors:  Chandrajit P Raut; Matthew H Kulke
Journal:  Oncologist       Date:  2011-02-23

7.  Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.

Authors:  Joseph D Valentino; Jing Li; Yekaterina Y Zaytseva; W Conan Mustain; Victoria A Elliott; Ji Tae Kim; Jennifer W Harris; Katherine Campbell; Heidi Weiss; Chi Wang; Jun Song; Lowell Anthony; Courtney M Townsend; B Mark Evers
Journal:  Clin Cancer Res       Date:  2014-01-17       Impact factor: 12.531

Review 8.  Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.

Authors:  P Gajate; T Alonso-Gordoa; O Martínez-Sáez; J Molina-Cerrillo; E Grande
Journal:  Clin Transl Oncol       Date:  2017-11-09       Impact factor: 3.405

9.  AKT and PTEN expression in human gastrointestinal carcinoid tumors.

Authors:  Susan C Pitt; Ruth Davis; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

Review 10.  Inhibition of mTOR in carcinoid tumors.

Authors:  Simona Grozinsky-Glasberg; Marianne Pavel
Journal:  Target Oncol       Date:  2012-08-12       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.